Post-translational modifications comparative identification and kinetic study of infliximab innovator and biosimilars in serum using capillary electrophoresis-tandem mass spectrometry - Archive ouverte HAL Accéder directement au contenu
Article Dans Une Revue Journal of Pharmaceutical and Biomedical Analysis Année : 2023

Post-translational modifications comparative identification and kinetic study of infliximab innovator and biosimilars in serum using capillary electrophoresis-tandem mass spectrometry

Identification comparative et étude cinétique des modifications post-traductionnelles d'infliximab et ses biosimilaires dans le sérum par électrophorèse capillaire couplée à la spectrométrie de masse

Résumé

Despite reports indicating the potential impact of post-translational modifications on the activity of a monoclonal anti-body, their prediction or monitoring post-administration remains a challenge. In addition, with the expiration of patents concerning the early generation of mAbs, the production of biosimilars is constantly increasing. Structural differences of biosimilars compared to the innovator product are commonly evaluated for the formulated product in the context of bio-similarity assessment. However, estimating their structural outcome after administration is particularly difficult. Due to the complexity of in vivo studies, there is a need to develop analytical strategies to predict PTMs consequently to their admin-istration and their impact on mAbs potency. Here, we identified and evaluated the modification kinetics of 4 asparagine deamidations and 2 aspartate isomerizations of infliximab innovator product (Remicade®) and two biosimilars (Inflectra® and Remsima®) in vitro using serum incubation at 37°C. The methodology was based on a bottom-up approach with capil-lary electrophoresis hyphenated with mass spectrometry analysis for an unequivocal assignment of modified and unmodi-fied forms. 2 asparagines demonstrated a gradual deamidation correlated with incubation time. The specific extraction efficiency was evaluated to determine possible changes in the antigen binding affinity of infliximab with the incubation. Results showed the possibility to achieve an additional aspect concerning biosimilarity assessment, oriented on the study of the structural stability after administration.
Fichier principal
Vignette du fichier
2023_Reinert et al - PTMs comparative identification and kinetic study of infliximab biosimilars in serum using CE-MSMS (accepted).pdf (852 Ko) Télécharger le fichier
Origine Fichiers produits par l'(les) auteur(s)

Dates et versions

hal-04599782 , version 1 (03-06-2024)

Identifiants

Citer

Tessa Reinert, Pascal Houzé, Nathalie Mignet, Yannis-Nicolas Francois, Rabah Gahoual. Post-translational modifications comparative identification and kinetic study of infliximab innovator and biosimilars in serum using capillary electrophoresis-tandem mass spectrometry. Journal of Pharmaceutical and Biomedical Analysis, 2023, 234, pp.115541. ⟨10.1016/j.jpba.2023.115541⟩. ⟨hal-04599782⟩
4 Consultations
2 Téléchargements

Altmetric

Partager

Gmail Mastodon Facebook X LinkedIn More